Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new drugs, such as Revuforj (revumenib), Komzifti (ziftomenib), and Vanflyta (a second-generation FLT3 inhibitor), indicates a trend toward more-targeted therapies. Moreover, both early- and late-phase pipelines for AML include various drug classes such as menin inhibitors, therapeutic vaccines, antibody-drug conjugates, and CAR T-cell therapies. Despite the recent failures of several drugs in late-phase development, we expect the expansion of existing therapies into additional patient populations and the approval of new treatments to lead to notable growth in the AML drug therapy market.<\/p>\n
Questions answered:<\/strong><\/p>\n Geographies:<\/strong> United States, EU5, Japan.<\/p>\n Primary research:<\/strong> Country-specific interviews with thought-leading hematologist-oncologists. Survey data collected for this and other Clarivate research.<\/p>\n Epidemiology:<\/strong> Diagnosed incidence of AML by country, clinically and market relevant drug-treatable populations.<\/p>\n Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key AML therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies.<\/p>\n Product description<\/strong><\/p>\n Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n\n
\n